| Net Cash Provided by (Used in) Operating Activities |
$14,182 |
USD |
|
Q4 2025 |
Q2 2027 |
| Net Cash Provided by (Used in) Financing Activities |
$28,592 |
USD |
|
Q4 2025 |
Q2 2027 |
| Net Cash Provided by (Used in) Investing Activities |
$16,800 |
USD |
|
Q4 2025 |
Q2 2027 |
| Common Stock, Shares Authorized |
75,000,000 |
shares |
|
Q4 2025 |
Q2 2027 |
| Common Stock, Shares, Issued |
4,500,000 |
shares |
|
Q4 2025 |
Q2 2027 |
| Common Stock, Par or Stated Value Per Share |
0.001 |
USD/shares |
|
Q4 2025 |
Q2 2027 |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect |
$2,390 |
USD |
|
Q4 2025 |
Q2 2027 |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents |
$110 |
USD |
|
Q4 2025 |
Q2 2027 |
| Deferred Tax Assets, Valuation Allowance |
$7,638 |
USD |
|
Q4 2025 |
Q2 2027 |
| Deferred Tax Assets, Operating Loss Carryforwards |
$7,638 |
USD |
|
Q4 2025 |
Q2 2027 |
| Amortization of Intangible Assets |
$11,560 |
USD |
|
Q4 2025 |
Q2 2027 |
| Depreciation, Depletion and Amortization |
$22,187 |
USD |
|
Q4 2025 |
Q2 2027 |